Dr Reddy’s Management Upbeat Despite Product Delays
Executive Summary
Dr Reddy’s had a generally positive Q4 but a slow ramp in some products in the US and potential delays in anticipated launches there are among the challenges that appear to have jaded investor outlook. Management commentary, though, was optimistic, with around 30 launches lined up for the US, a China/India thrust and M&A staying an important cog for growth.
You may also be interested in...
Alvogen and Reddy’s Cleared Over US Rivals To Suboxone
Alvogen and Dr Reddy’s do not infringe key patents protecting Indivior’s Suboxone Film, the US Court of Appeals has confirmed. But Teva continues to fall foul of a production patent running until 2024.
Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe
Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.
Record Dr Reddy's US Launches In Q3 Set Tone For Earnings Pick Up?
Dr Reddy’s has had a record number of US launches in Q3 with potentially more in store and now a new US CEO to steer things through, improving outlook for a significant revival in earnings. But risks of delays and competition in certain key anticipated launches in 2019 could dull prospects.